While TGFβ1 is thought to be the primary isoform expressed in the immune system, our data suggest that TGFβ1 and TGFβ3 are both highly detectable in the tumor microenvironment and may play alternate roles in regulating T cell biology, thus offering alternate targets for anti-cancer therapy. Here, TGFB1 is linked to neoplasm.